Biomatrica Announce Marketing Agreement with QIAGEN
News Jun 07, 2007
The agreement provides QIAGEN with exclusive marketing rights for Biomatrica’s existing products for the storage of purified DNA beginning June, 2008. SampleMatrix® DNA storage products will continue to be available directly from Biomatrica for the next year.
Biomatrica’s SampleMatrix® products make it possible for scientists to store and ship purified DNA and cell samples at room temperature. Retrieval of DNA is simple; just add water. All samples are ready for use in any downstream application such as PCR, transformation, transfection, sequencing, genotyping, STR analysis, etc.
In addition, the product offering includes affordable sample management software, providing scalable solutions for customers in low and high-throughput laboratories and bio-banking databases.
“The strategic partnership with QIAGEN is the ideal arrangement to build Biomatrica’s innovative and cost effective products for DNA stabilization. The partnership combines Biomatrica’s know-how in biostabilization and manufacturing and QIAGEN’s marketing power to reach into all fields of the research and forensic communities,” said Judy Muller-Cohn Biomatrica’s Chief Executive Officer and co-founder.
“The Biomatrica-QIAGEN relationship gives Biomatrica’s products a stamp of approval from the market leader in quality DNA products,” said Rolf Muller, Biomatrica’s Chief Scientific Officer and co-founder. “It’s a powerful combination of innovation and credibility.”
"As evidenced by significant internal and partnered initiatives, QIAGEN sees significant value in a broad and deep portfolio in stabilization and storage solutions for biological samples. We are pleased to today announce a significant, synergistic expansion to our leadership position in this area,” said Peer M. Schatz, QIAGEN’s Chief Executive Officer.
Schatz continued: “The SampleMatrix® technology uses fascinating principles of nature for stabilizing biomolecules which then can be shipped and even stored at room temperature to be used in conjunction with a wide range of subsequent purification procedures and analytical processes. QIAGEN’s technology and marketing power, together with the development capabilities and know how and intellectual property rights of Biomatrica, provide the basis for a very strong, successful strategic partnership to market and develop products and methods which leverage QIAGEN’s sample technology and assay leadership”
During the course of the strategic partnership, Biomatrica’s SampleMatrix® technology and QIAGEN's exclusive rights are expected to be broadened to include the stabilization, shipping and storage of DNA molecules in blood and buccal swab samples for subsequent purification of the stabilized DNA for any kind of downstream application and for use in all markets. The existing and future products will be manufactured by Biomatrica and exclusively marketed and sold by QIAGEN.
CRISPR Causes More Genome Damage Than First ThoughtNews
Researchers have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.
Potential Treatment for Rare Inherited CancersNews
Studying two rare inherited cancer syndromes, scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery suggests a promising strategy for treatment with drugs recently approved for other forms of cancer, said the researchers.READ MORE